scholarly journals Saving the Fetus in Maternal Schizophrenia: The Role and Safety of Electroconvulsive Therapy (ECT) in Pregnancy.

2018 ◽  
Vol 1 (1) ◽  
pp. 48-52
Author(s):  
Othman Abdul Karim ◽  
Noraslawati R ◽  
Anisah J ◽  
Syaratul Emma H
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Electroconvulsive Therapy ◽  
First Trimester ◽  
Treatment Resistant ◽  
Pharmacological Interventions ◽  
Antipsychotic Medications ◽  
Long Duration ◽  
Clinical Dilemma ◽  
In Pregnancy

Introduction: Managing schizophrenia during pregnancy often presents a clinical dilemma. Although pharmacological interventions are mostly effective for these disorders during pregnancy, there are few drawbacks for this approach. The potential teratogenicity and long duration of interventions required to control the symptoms somehow limits its usage during pregnancy.Here we described a case report of treatment-resistant schizophrenia successfully treated with ECT without obvious complication to the mother and her baby.Conclusion: Electroconvulsive therapy is an ideal alternative treatment for a patient with schizophrenia during pregnancy. ECT also will eliminate the potential side effects of antipsychotic medications on the mother and teratogenicity effect to the fetus, especially during the first trimester.

scholarly journals Acute onset clozapine-induced hyperglycaemia: A case report

2019 ◽  
Vol 32 (2) ◽  
pp. e100045 ◽  
Author(s):  
Pradeep Kumar ◽  
Dheerendra Kumar Mishra ◽  
Nimisha Mishra ◽  
Sunil Ahuja ◽  
Gyanendra Raghuvanshi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Case Report ◽  
Side Effects ◽  
Atypical Antipsychotic ◽  
Time Frame ◽  
Acute Onset ◽  
Antipsychotic Medications ◽  
Pathophysiological Mechanisms ◽  
Hypoglycaemic Agent

Clozapine is an atypical antipsychotic which is described to have higher efficacy among all available antipsychotic medications. Clozapine is reserved especially for resistant schizophrenia due to its side effects. Clozapine-induced metabolic syndrome and hyperglycaemia are common long-term side effects and are responsible for increased mortality in patients with schizophrenia. In this case, a patient with resistant schizophrenia was presented with acute-onset hyperglycaemia and delirium with the use of clozapine within a week. Withdrawal of clozapine in the patient led to the improvement in delirium and hyperglycaemia without the use of any hypoglycaemic agent. This case supports the notion that in certain cases clozapine can induce hyperglycemia through possible direct pathophysiological mechanisms within a shorter time frame.

Delirium on clozapine: A tale of friend turned foe-A case report

2020 ◽  
pp. 009121742097282 ◽  
Author(s):  
Aparna Das ◽  
Rebecca Minner ◽  
Lewis Krain ◽  
John Spollen
Keyword(s):  
Case Report ◽  
Clinical Practice ◽  
Side Effects ◽  
Adverse Effects ◽  
Older Adult ◽  
Psychiatric Illness ◽  
Management Strategies ◽  
Treatment Resistant ◽  
Drug Of Choice ◽  
Life Threatening

Treatment resistant schizophrenia (TRS) is often encountered in clinical practice. Clozapine remains the drug of choice in the management of TRS. Several studies have shown that clozapine is the most effective antipsychotic medication to date for TRS. But it is also well known that it has multiple side effects. Some side effects are transient and relatively benign, while other adverse effects are menacing, serious and life-threatening. Delirium may occur with clozapine and is a therapeutic challenge as there is always a risk of precipitating delirium on clozapine rechallenge. Limited management strategies are available as alternatives for the management of psychiatric illness stabilized on clozapine. In this case report, we describe an older adult patient who developed delirium on clozapine. The aims of this case report are to discuss the mechanism by which clozapine leads to delirium, revisit various factors which could possibly lead to delirium, and discuss the different management strategies available for management of psychiatric illness for a patient previously stabilized on clozapine.

Brain-derived neurotrophic factor and electroconvulsive therapy in a schizoaffective patient with treatment-resistant paranoid-hallucinatory symptoms

2011 ◽  
Vol 26 (S2) ◽  
pp. 1148-1148
Author(s):  
G. Martinotti ◽  
V. Ricci ◽  
M. Di Nicola ◽  
C. Caltagirone ◽  
P. Bria ◽  
...  
Keyword(s):  
Case Report ◽  
Electroconvulsive Therapy ◽  
Neurotrophic Factor ◽  
Poor Response ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Treatment Resistant ◽  
Schizophrenic Patients ◽  
General Improvement ◽  
The Relationship

It has been proposed that deficits in the production and the utilization of brain-derived neurotrophic factor (BDNF) may contribute to the pathogenesis of schizophrenia. At the same time, electroconvulsive therapy (ECT) has been shown to induce a robust increase of BDNF protein in animal models. These findings suggest that one putative mechanism of action of ECT is the regulation of BDNF and/or related neurotrophins. In this case report a 54-year-old man with severe treatment-resistant schizophrenic symptoms was treated with ECT. In order to evaluate the effect of ECT on BDNF serum levels, we collected a blood sample before each ECT session. During the course of ECT treatment the paranoid and hallucinatory symptoms gradually improved while BDNF levels increased over time. In addition, there was a general improvement of its positive and negative schizophrenic symptoms and depressive state.In conclusion, this case report further validates the therapeutic efficacy of ECT in schizophrenic patients with inadequate or poor response to traditional treatments. Moreover, ECT therapeutic effect is associated with an increase in BDNF serum levels. Further studies are needed to characterize the relationship between BDNF and ECT in patients with schizophrenia symptoms.

scholarly journals Suicide due to fear of COVID-19, in pregnancy, lead to Neonatal malformations: A case report

2021 ◽  
Author(s):  
Javad Boskabadi ◽  
Saeed Kargar-Soleiman abad ◽  
shahrokh mehrpishe ◽  
Elham Pishavar ◽  
Roya Farhadi
Keyword(s):  
Mental Health ◽  
Case Report ◽  
Antipsychotic Drugs ◽  
First Trimester ◽  
Limited Data ◽  
First Trimester Of Pregnancy ◽  
In Pregnancy

There is limited data about various effect of COVID-19 in pregnancy. The Covid-19 pandemic can increase anxiety or schizophrenia exacerbation. Neonatal malformations from antipsychotic drugs exposures during first trimester of pregnancy have been reported. However, their effect near delivery have been less studied. Keywords: Covid-19, pregnancy, mental health, neonatal malformations

scholarly journals Rapid-onset supraventricular tachycardia following clozapine initiation and its management with verapamil: a case report

2019 ◽  
Vol 6 (2) ◽  
pp. 547
Author(s):  
Afnan A. Alwabili
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Adverse Effects ◽  
Supraventricular Tachycardia ◽  
Low Dose ◽  
Rapid Onset ◽  
Treatment Resistant ◽  
Early Stages ◽  
Drug Of Choice ◽  
Cardiovascular Side Effects

Clozapine is the drug of choice for treatment-resistant schizophrenia. However, the use of clozapine is limited by its serious adverse effects, which often underlie its discontinuation. The cardiovascular side effects that raise safety concerns include tachycardia, myocarditis and cardiomyopathy. The development of clozapine-induced tachycardia is usually observed on higher dosage especially at early stages of treatment. Here, author presented the case of a patient with treatment-resistant schizophrenia who developed asymptotic supraventricular tachycardia despite low dose of clozapine at the second day of treatment. Additionally, author explored the possibility of clozapine re-challenge in combination with verapamil treatment.

scholarly journals Worsening of movement disorder following treatment with electroconvulsive therapy in a patient with Huntington’s disease

2019 ◽  
Vol 12 (8) ◽  
pp. e230389 ◽  
Author(s):  
Hesitha Abeysundera ◽  
Allan Campbell ◽  
Shanthi Sarma
Keyword(s):  
Case Report ◽  
Huntington's Disease ◽  
Movement Disorder ◽  
Huntington’S Disease ◽  
Electroconvulsive Therapy ◽  
Movement Disorders ◽  
Treatment Resistant Depression ◽  
Treatment Resistant ◽  
Medical Practitioners ◽  
Resistant Depression

This paper describes a patient who presented with treatment-resistant depression with comorbid anxiety symptoms in the context of Huntington’s disease (HD) and developed worsening movement disorder symptoms after commencing electroconvulsive therapy (ECT) for depression. The aim of this case report is to provide medical practitioners with a greater awareness of the possibility of worsening movement disorders when using ECT for depression in a patient with HD.

scholarly journals Young patient with treatment-resistant schizophrenia drastically improved by combination of clozapine and maintenance electroconvulsive therapy: a case report

2019 ◽  
Vol Volume 12 ◽  
pp. 185-188 ◽  
Author(s):  
Masashi Ito ◽  
Yasuto Kunii ◽  
Sho Horikoshi ◽  
Itaru Miura ◽  
Shuntaro Itagaki ◽  
...  
Keyword(s):  
Case Report ◽  
Young Patient ◽  
Electroconvulsive Therapy ◽  
Treatment Resistant

Acute electroconvulsive therapy in the elderly with schizophrenia and schizoaffective disorder: a literature review

2019 ◽  
Vol 27 (5) ◽  
pp. 472-476 ◽  
Author(s):  
David Kumagaya ◽  
Graeme Halliday
Keyword(s):  
Elderly Patients ◽  
Electroconvulsive Therapy ◽  
Literature Search ◽  
The Elderly ◽  
Psychotic Symptoms ◽  
Medical Complications ◽  
Treatment Resistant ◽  
Antipsychotic Medications ◽  
Valuable Treatment ◽  
Almost All

Objectives: This study reviewed the evidence regarding the efficacy of acute electroconvulsive therapy for primary psychotic conditions in the elderly. Methods: A literature search was performed using the Medline, Embase and Cochrane databases. Results: Acute electroconvulsive therapy resulted in an improvement of psychotic symptoms in almost all elderly patients, a large proportion of whom had treatment-resistant conditions. No electroconvulsive therapy related fatalities or severe medical complications were encountered. Conclusions: Acute electroconvulsive therapy may present a valuable treatment modality for elderly patients with primary psychotic conditions who do not respond adequately to antipsychotic medications.

Sign in / Sign up

Export Citation Format

Share Document